Contact
Please use this form to send email to PR contact of this press release:
Newton Biocapital I Invests in J-Pharma Co.,Ltd. for Drug Development Targeting LAT1 for Cancer and Autoimmune Diseases
TO:
Alain Parthoens
Newton Biocapital I - Belgium
+32 476 66 08 85